Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18958956 | COMPOSITIONS OF HYDROXYPROPYL-BETA-CYCLODEXTRIN AND METHODS OF PURIFYING THE SAME | November 2024 | August 2025 | Allow | 9 | 2 | 0 | No | No |
| 18813368 | COMPOSITIONS OF HYDROXYPROPYL-BETA-CYCLODEXTRIN AND METHODS OF PURIFYING THE SAME | August 2024 | September 2025 | Allow | 13 | 2 | 0 | Yes | Yes |
| 18062416 | Neoepitope Vaccine Delivery Vehicle and Methods of Making the Same | December 2022 | April 2025 | Allow | 29 | 1 | 1 | Yes | No |
| 17915690 | LARGE SCALE PROCESS FOR PREPARING 1,2,4, 6-TETRA-O-ACETYL-3-AZIDO-3-DEOXY-D-GALACTOPYRANOSIDE | September 2022 | February 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17949926 | GLYCAN PREPARATIONS FOR THE TREATMENT OF INFECTION | September 2022 | December 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17906373 | Etoposide Glycosides, Methods Of Making, And Uses Thereof As An Anti-Cancer Drug | September 2022 | December 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17800563 | COMPOSITIONS AND THERAPEUTIC USES OF CANNABIDIOL | August 2022 | September 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17798549 | ALLULOSE CONCENTRATES IN SOLID AMORPHOUS FORM | August 2022 | December 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17881527 | COMPOSITIONS AND METHODS FOR RELIEVING EFFECTS OF ALCOHOL CONSUMPTION | August 2022 | April 2025 | Abandon | 32 | 2 | 1 | No | No |
| 17759775 | MODULATION OF IMMUNE CELLS | July 2022 | October 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17782251 | NAD-PRECURSORS AND DIETARY RESTRICTION FOR TREATING AGE RELATED MEDICAL CONDITIONS | June 2022 | November 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17772775 | PHARMACEUTICAL COMPOSITIONS CONTAINING ALGINATE OLIGOSACCHARAIDE DIACID | April 2022 | October 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17766984 | METHOD FOR PRODUCING GLYCOSIDE COMPOUND | April 2022 | December 2025 | Allow | 44 | 2 | 0 | No | No |
| 17761963 | PROCESSES FOR EXTRACTING AND PURIFYING CHITIN BY USING GREEN SOLVENTS | March 2022 | October 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17641294 | NEW CYCLODEXTRIN DIMERS AND THEIR USES THEREOF AS CHEMICAL SCAVENGERS | March 2022 | December 2025 | Allow | 45 | 1 | 0 | Yes | No |
| 17640204 | USE OF NMN FOR THE PREVENTION AND/OR TREATMENT OF PAIN, AND CORRESPONDING COMPOSITIONS | March 2022 | December 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17753336 | LIGAND-2'-MODIFIED NUCLEIC ACIDS, SYNTHESIS THEREOF AND INTERMEDIATE COMPOUNDS THEREOF | February 2022 | November 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17630335 | PHARMACOLOGICAL INHIBITORS OF THE ENL YEATS DOMAIN | January 2022 | December 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17648771 | GALACTOOLIGOSACCHARIDE COMPOSITION FOR USE IN PREVENTING OR TREATING COGNITIVE DYSFUNCTION AND EMOTIONAL DISTURBANCES IN NEUROPSYCHIATRY ILLNESSES OR AGEING | January 2022 | December 2025 | Abandon | 47 | 2 | 0 | No | No |
| 17566724 | METHOD FOR PREPARING V-TYPE GRANULAR POROUS STARCH | December 2021 | August 2025 | Allow | 44 | 1 | 0 | Yes | No |
| 17546180 | Method for Enhancing Tyrosinase Inhibitory Activity | December 2021 | April 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17525054 | METHOD FOR SUPPRESSING INTERVERTEBRAL DISC PAIN | November 2021 | July 2025 | Allow | 44 | 2 | 0 | Yes | No |
| 17609701 | SUBSTITUTED SULFONAMIDE PYRROLOPYRIDINES AS JAK INHIBITORS | November 2021 | May 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17603094 | COMPOSITION FOR ORAL ADMINISTRATION WITH CONTROLLED RELEASE PROPERTIES COMPRISING COMPLEX OF CLAY MINERALS, METHOD FOR PREPARING SAME, AND METHOD FOR CONTROLLING RELEASE PROPERTIES | October 2021 | April 2025 | Allow | 42 | 2 | 0 | Yes | No |
| 17599447 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | September 2021 | May 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17599465 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | September 2021 | May 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17300676 | MULTIVALENT LIGAND CLUSTERS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | September 2021 | May 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17441092 | NANOCELLULOSE DISPERSION LIQUID AND METHOD FOR PRODUCING THE SAME | September 2021 | July 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17432497 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF PROLIFERATIVE DISORDERS | August 2021 | June 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17400488 | PRODUCTION METHOD FOR OLIGONUCLEOTIDES | August 2021 | December 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17430422 | EXTRACTION APPARATUS, EXTRACTION METHOD, AND FLUIDIC CHIP FOR EXTRACTING TARGET MATERIAL | August 2021 | June 2025 | Allow | 46 | 2 | 0 | Yes | No |
| 17429346 | GLYONIC LIQUIDS AND USES THEREOF | August 2021 | June 2025 | Abandon | 46 | 2 | 0 | Yes | No |
| 17427479 | METHOD OF SYNTHESIZING SINGLE-STRANDED NUCLEOTIDE SEQUENCE, BLOCKED NUCLEOSIDE TRIPHOSPHATES AND RELATED METHODS | July 2021 | February 2026 | Allow | 55 | 3 | 0 | Yes | No |
| 17420293 | COMPOSITIONS AND METHODS FOR MODULATING HAIR GROWTH | July 2021 | March 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17354521 | METHOD FOR IDENTIFYING MODULATORS OF NOTCH SIGNALING | June 2021 | March 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17414712 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | June 2021 | January 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17338022 | FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES THROUGH REDUCTIVE AMINATION FOR ENHANCED MS SIGNALS | June 2021 | March 2025 | Abandon | 45 | 1 | 1 | Yes | No |
| 17294804 | NAPHTHYRIDINONE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | May 2021 | March 2025 | Allow | 46 | 2 | 0 | Yes | No |
| 17203674 | METHODS OF IDENTIFYING RESPONSES TO MAP KINASE INHIBITION THERAPY | March 2021 | March 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17258914 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | January 2021 | September 2024 | Allow | 44 | 1 | 0 | Yes | No |
| 17056466 | PHENYL-SUBSTITUTED DIHYDRONAPHTHYRIDINE COMPOUND AND USE THEREOF | November 2020 | July 2025 | Allow | 56 | 4 | 0 | Yes | No |
| 17083720 | INJECTABLE CRYOGEL VACCINE DEVICES AND METHODS OF USE THEREOF | October 2020 | October 2023 | Abandon | 36 | 4 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner CREWS, JARET JAMES works in Art Unit 1691 and has examined 23 patent applications in our dataset. With an allowance rate of 47.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 44 months.
Examiner CREWS, JARET JAMES's allowance rate of 47.8% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CREWS, JARET JAMES receive 1.74 office actions before reaching final disposition. This places the examiner in the 37% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by CREWS, JARET JAMES is 44 months. This places the examiner in the 14% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +84.6% benefit to allowance rate for applications examined by CREWS, JARET JAMES. This interview benefit is in the 100% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 37.5% of applications are subsequently allowed. This success rate is in the 85% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 66.7% of cases where such amendments are filed. This entry rate is in the 90% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 4% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.